Developer of automated microscopy device designed to improve healthcare for everyone through smarter blood testing.
Developer of automated microscopy device designed to improve healthcare for everyone through smarter blood testing.
Diagnostic Equipment📍 Tel Aviv, IsraelFounded 2010
Current Valuation
$594.98M
as of 2020-Q3
PRIVATE
QL Price
$594.98M
0% vs last round
QuantLogix's current estimate for Sight Diagnostics, published 2026-09-27 — in line with the last disclosed round of $594.98M (2020-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$594.98M
2020-Q3
weight 0.02
How this price has held up
No round has priced for Sight Diagnostics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Sight Diagnostics, 2026-09-27 (7ebe0c4129a54083).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Sight Diagnostics going public?
No. Sight Diagnostics is private and has not filed to go public. There is no S-1 on file.
What is Sight Diagnostics' valuation in 2026?
Sight Diagnostics is valued at $594.98M as of 2020-Q3, set by its Series D ($71M, Jul 2020). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Sight Diagnostics filed an S-1?
No public S-1 is on file for Sight Diagnostics.
How much has Sight Diagnostics raised?
Sight Diagnostics has raised $123.76M in total, most recently a Series D of $71M in Jul 2020.
Is Sight Diagnostics publicly traded — can you buy Sight Diagnostics stock?
No. Sight Diagnostics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Sight Diagnostics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2010
HQ
Tel Aviv, Israel
Employees
130
Total Raised
$123.76M
Last Round
Series D — $71M (Jul 2020)
IPO Status
private
Fundraising Status
Series D · $71M · 6y 2mo ago
privateTotal raised $123.76M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$71M
Jul 2020
—
$594.98M
Talent Signal
No public careers page or job board could be found for Sight Diagnostics as of 2026-09-17. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2020-Q3. Refreshed quarterly.